CardioPulmonary Resuscitation With Argon (CPAr) Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Noble gas Argon.
- Who it may be relevant to
- Registry conditions: Cardiac Arrest, Out-Of-Hospital, Cardiac Arrest With Successful Resuscitation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Preclinical studies suggest that argon (Ar) might diminish the neurological and myocardial damage after any hypoxic-ischemic insult. Indeed, Ar has been tested in different models of ischemic insult, at concentrations ranging from 20% up to 80%. Overall, Ar emerged as a protective agent on cells, tissues and organs, showing less cell death, reduced infarct size and faster functional recovery. More specifically, encouraging data has been reported in animal studies on cardiac arrest (CA) in which a better and faster neurological recovery was achieved when Ar was used in the post-resuscitation ventilation. More importantly, these benefits have been replicated in different studies, enrolling both small and large animals. Finally, ventilation with Ar in O2 has been demonstrated to be safe both in animals and humans. Based on this evidence, a clinical translation is advocated. Thus, the CardioPulmonary resuscitation with Argon - CPAr trial has been conceived. The trial initially started as phase I-II trial to specifically address the question about the safety of the post resuscitation Ar-treatment. The available data on the first 30 randomized patients, evaluated by the Data Safety Monitoring Board (DSMB), were considered absolutely reassuring with regard to the safety of the experimental treatment. In this perspective, the DSMB supported the continuation of the study as a phase II trial, maintaining the study protocol in all its aspects. Thus, the aim of the CPAr trial is now to evaluate efficacy in reducing post-CA neurological injury of Ar/O2 ventilation in patients resuscitated from CA.
Detailed description
The trial is a multicenter, randomized, controlled, single blinded, phase II and pre marketing study in patients resuscitated from Out-of-hospital cardiac arrest (OHCA).
All eligible patients will be treated in full and documented compliance with the European ResuscitationCouncil (ERC)/European Society of Intensive Care Medicine (international guidelines and local post resuscitation protocols). In addition, a randomized assignment ensures a strict comparability for both the periods of data collection of safety end-points (to be assessed blindly by the events Committee): the four hours of duration of study treatment, and the longer period of possibly related clinical events during 6 months follow up.
Interventions
- Drug Noble gas Argon
Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
Primary outcome measures
- Neuronal preservation [Time frame: 48 hours]
Secondary outcome measures (6)
- Myocardial preservation [Time frame: Up to 96 hours]
- Brain injury [Time frame: 96 hours]
- Survival [Time frame: ICU discharge (assessed up to 7 days), 1-month, 6 months]
- Neurological recovery [Time frame: ICU discharge (assessed up to 7 days), 1-month, 6 months]
- Multiorgan function [Time frame: Up to 96 hours]
- Incidence of Treatment-Emergent Adverse Events [Time frame: 1 month]
Eligibility criteria
Inclusion criteria
- ICU admission after resuscitation from witnessed non-traumatic out-of-hospital cardiac arrest (OHCA) of presumably cardiac etiology with a presenting shockable rhythm;
- age ≥ 18 years;
- unconsciousness after return of spontaneous circulation (ROSC);
- duration of CPR ≤ 40 mins;
- initiation of study intervention ≤ 4 hrs from ROSC;
- stable SaO2 ≥ 94% with a FiO2 of 30%.
Exclusion criteria
- Non-witnessed CA;
- CA of traumatic origin or from a non-presumably cardiac cause;
- CA with a non-shockable presenting rhythm (pulseless electrical activity and asystole);
- female of childbearing potential defined as younger of 50 years;
- pregnancy;
- known terminal illness;
- pre-CA cerebral performance category (CPC) ≥ 3;
- initiation of the study intervention > 4 hrs from ROSC;
- participation to another clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Italy · 9 centers
- Ospedale Policlinico San Martino di Genova — Genova
- Ospedale San Gerado — Monza
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan
- Azienda Ospedaliero - Universitaria di Parma — Parma
- Ospedale Civile Santa Maria degli Angeli di Pordenone — Pordenone
- Arcispedale Santa Maria Nuova di Reggio Emilia — Reggio Emilia
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma
- Ospedale Santa Chiara di Trento — Trento
- … and 1 more center
Publications
- Ristagno G, Staszewsky L, Merigo G, Magliocca A, Cucino A, Meessen J, Fumagalli F, Pozzi M, Galazzi A, Sandroni C, Meneguzzi M, Marangone A, Robba C, Roman-Pognuz E, Salati G, Picetti E, Novelli D, Bellani G, Panigada M, Wik L, Garattini S, Foti G, Antonelli M, Zanier E, Grasselli G, Latini R; CPAr Study group. CardioPulmonary resuscitation with Argon (CPAr): A protocol for a randomised controlled PMID 41079544
Identifiers
NCT: NCT05482945 · IRFMN-7557